EAS 2020 — What are the best practices in secondary prevention post-acute coronary syndrome?


  • Suresh Palle
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients experiencing an acute coronary syndrome (ACS) have a high risk for recurring events, which necessitates early implementation of optimal pharmacological and non-pharmacological secondary prevention measures.
  • Dr K. Koskinas, Switzerland, reviews the best recent practices for secondary prevention in this very high-risk patients.

Key highlights

  • Potential interventions include antithrombotic treatment, lipid-lowering treatment and treatment for metabolic disorders and inflammation.
  • In the most recent 2020 European Society of Cardiology (ESC) guidelines, non-pharmacological interventions such as improved lifestyle factors, cognitive behavioural interventions and annual influenza vaccination are listed as Class I recommendations.
  • There is a gradual shift towards tailored antithrombotic treatment post-ACS determined by each patient’s ischemic and bleeding risk.
  • Low-dose aspirin remains the recommended long-term antithrombotic treatment.
  • Addition of a second antiplatelet treatment for 12 months or even more is recommended in the absence of contraindications or excessive bleeding risk.
  • The use of prasugrel is preferred over ticagrelor in patients with non-ST-elevation ACS who proceed to percutaneous coronary intervention.
  • 12-month dual antiplatelet therapy is typically recommended for most patients; however, the duration can be reduced to 3 or 6 months and the intensity can be de-escalated from prasugrel/ticagrelor to clopidogrel in some properly selected patients.
  • However, prolonged antithrombotic treatment (>12 months; antiplatelet/anticoagulant drug+aspirin) may be considered in some patients.
  • For lipid management, the 2019 ESC/European Atherosclerosis Society guidelines recommended lower low-density lipoprotein-cholesterol (LDL-C) targets than the 2016 guidelines:
    • Very high risk:
    • High risk:
  • In all patients with ACS, high-dose statins are recommended as early as possible regardless of initial LDL-C values.
  • If LDL-C goals are not achieved after 4-6 weeks with maximally tolerated statin, combination with ezetimibe is recommended.
  • If LDL-C goals are not achieved after 4-6 weeks with statin+ezetimibe combination, the addition of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is recommended.
  • PCSK9 inhibitor should be considered early after the event (if possible, during hospitalization) in patients with ACS and LDL-C above targets despite statin+ezetimibe therapy.
  • Anti-inflammatory drugs have also shown clinical benefits in patients with established coronary artery disease.
  • In a randomized trial involving patients with chronic coronary disease, cardiovascular risk reduction was >30% with low-dose colchicine vs placebo (HR, 0.69; 95% CI, 0.57-0.83; P<.001>
  • In COLCOT trial, low-dose colchicine vs placebo significantly reduced the risk for ischemic cardiovascular events among patients with recent myocardial infarction (MI; HR, 0.77; 95 CI%, 0.61-0.96; P=.02).
  • In CANTOS trial, anti-inflammatory therapy with canakinumab vs placebo significantly reduced recurrent cardiovascular events among patients with previous MI and high-sensitivity C-reactive protein >2 mg/L (HR, 0.85; 95% CI, 0.74-0.98; P=.021).
  • Anti-inflammatory treatments are not yet recommended for clinical use, but look promising to further lower the risk for recurrent events in patients with ACS.